Article Information
History
- September 9, 2024.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Ivan Gentile1,
- Riccardo Scotto1,*,
- Maria Michela Scirocco1,
- Francesco Di Brizzi1,
- Federica Cuccurullo1,
- Maria Silvitelli1,
- Luigi Ametrano1,
- Francesco Antimo Alfè1,
- Daria Pietroluongo1,
- Irene Irace1,
- Mariarosaria Chiariello1,
- Noemi De Felice1,
- Simone Severino1,
- Giulio Viceconte1,
- Nicola Schiano Moriello1,
- Alberto Enrico Maraolo1,
- Antonio Riccardo Buonomo1,
- Agnese Giaccone2,
- Federico II COVID team°
- 1Department of Clinical Medicine and Surgery – Section of Infectious Diseases, University of Naples Federico II, Naples, Italy
- 2AORN Ospedali dei Colli, Cotugno Hospital, Department of Infectious Diseases, Unit of Geriatric Infectious Diseases, Naples, Italy
- ↵*Corresponding author:
Riccardo Scotto, M.D., Ph.D. Department of Clinical Medicine and Surgery – Section of Infectious Diseases. University of Naples Federico II, Via Sergio Pansini 5, 80131, Naples, Italy, Email: riccardo.scotto{at}unina.it (work) ri.scotto{at}gmail.com (personal), Phone: +39 081 746 30 98 (work)
Posted September 09, 2024.
Efficacy of Molnupiravir in reducing the risk of severe outcome in patients with SARS-CoV-2 infection: a real-life full-matched case-control study (SAVALO Study)
